Zentexia is a Danish R&D company specialized in developing new small molecules aimed at reversing aging at the cellular level.
Zentexia develops novel therapeutic concepts for the life science industries through a proprietary interdisciplinary approach based on artificial intelligence (AI) and advanced systems biology.
AI is employed in all stages of development to provide pioneering efficacy, minimize development risk and optimize the probability of success.
Zentexia’s novel active small molecules are aimed at a range of life science applications - pharmaceutical as well as adjacent regulatory categories like medical devices.
Zentexia’s technologies are owned 100% by sister project companies dedicated to asset maturation in cooperation with investors or partners.